- Home
- GCMG vs ZVRA Comparison
GCMG vs ZVRA Comparison
Compare GCMG & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMG
- ZVRA
- Stock Information
- Founded
- GCMG 1971
- ZVRA 2006
- Country
- GCMG United States
- ZVRA United States
- Employees
- GCMG N/A
- ZVRA N/A
- Industry
- GCMG Finance/Investors Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- GCMG Finance
- ZVRA Health Care
- Exchange
- GCMG Nasdaq
- ZVRA Nasdaq
- Market Cap
- GCMG 554.1M
- ZVRA 511.6M
- IPO Year
- GCMG N/A
- ZVRA 2015
- Fundamental
- Price
- GCMG $11.75
- ZVRA $8.49
- Analyst Decision
- GCMG Hold
- ZVRA Strong Buy
- Analyst Count
- GCMG 5
- ZVRA 7
- Target Price
- GCMG $13.20
- ZVRA $21.20
- AVG Volume (30 Days)
- GCMG 301.5K
- ZVRA 550.1K
- Earning Date
- GCMG 02-11-2025
- ZVRA 11-12-2024
- Dividend Yield
- GCMG 3.75%
- ZVRA N/A
- EPS Growth
- GCMG N/A
- ZVRA N/A
- EPS
- GCMG N/A
- ZVRA N/A
- Revenue
- GCMG $462,593,000.00
- ZVRA $24,489,000.00
- Revenue This Year
- GCMG $16.00
- ZVRA N/A
- Revenue Next Year
- GCMG $12.44
- ZVRA $383.29
- P/E Ratio
- GCMG $155.00
- ZVRA N/A
- Revenue Growth
- GCMG 8.20
- ZVRA 47.85
- 52 Week Low
- GCMG $8.05
- ZVRA $4.20
- 52 Week High
- GCMG $12.58
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- GCMG 40.32
- ZVRA 44.11
- Support Level
- GCMG $11.66
- ZVRA $8.17
- Resistance Level
- GCMG $12.55
- ZVRA $8.73
- Average True Range (ATR)
- GCMG 0.28
- ZVRA 0.41
- MACD
- GCMG -0.10
- ZVRA -0.10
- Stochastic Oscillator
- GCMG 10.11
- ZVRA 21.77
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.